Novel Technologies

Novel Technologies

Two subcutaneous therapies are currently being investigated.
MLOF is open to all people with hemophilia A and B.
More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.
The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.
Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.
An update on FVII gene therapy and more.
Updates on Daklinza, Technivie, and the ACE910 trial
Five pilot sites have been approved and first patients enrolled
A workshop on new bleeding disorders therapies provided insights on improved clotting factors, immune responses to new treatments and gene...
Chat Icon
Need Info? Ask NHF!
Contact HANDI, NHF's resource center for additional information on bleeding disorders.